search
Back to results

Treatment of Upper Limb Chronic Neuropathic Pain by Electrical Stimulation of the Brachial Plexus Nerve Roots (SIMPLEX)

Primary Purpose

Neuralgia

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
electrical stimulation of the brachial plexus nerve roots
sham stimulation
Sponsored by
Centre Hospitalier Universitaire de Nice
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neuralgia

Eligibility Criteria

18 Months - 80 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Eligibility will be determined by trained clinicians with expertise in chronic pain and neuropathic pain. Patients between 18 and 80 years old suffering from moderate to severe (VAS score >5/10) chronic (duration> 12 months) neuropathic (DN4 score ≥ 4/10) unilateral pain - located in the upper limb. from peripheral origin, including complex regional pain syndrome type I and II, post-traumatic or post surgical pain. refractory to first and second line treatments for neuropathic pain according recent French recommendations and guidelines[6], including serotonin- noradrenaline reuptake inhibitor (SNRI) antidepressants (duloxetine and venlafaxine), gabapentin, pregabalin, tricyclic antidepressants, topical lidocaine, high-concentration capsaicin patches, psychotherapy and combinations of them. Patient have signed informed consent - Patient benefiting from French social insurance system Exclusion Criteria: Brachial plexus avulsion Post-zoster neuropathic pain Phantom limb pain Patient unable to fill a self-administered questionnaire Patients with a chronic disease requiring repeated MRI monitoring Patients with contra-indication to general anesthesia, surgery or percutaneous BP approach. Patients with other pacemakers (cardiac pacemaker or defibrillator) or patients with a high risk to use a defibrillator due to a known cardiac disorder. Patients with instable neuropsychological or psychiatric disorders Vulnerable patients: pregnant or breast feeding, minor, adult under guardianship or deprived freedom

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    BP PNS (experimental group)

    sham stimulation (control group).

    Arm Description

    Patients with refractory upper limb neuropathic pain treated by chronic electrical stimulation of the brachial plexus nerve roots

    Patients with refractory upper limb neuropathic pain treated by sham stimulation

    Outcomes

    Primary Outcome Measures

    efficacity
    evaluation by the patient with quizz EQ5D (worse: 0-better: 20)
    efficacity
    evaluation by the patient with quizz VAS (worse: 0- better: 100)

    Secondary Outcome Measures

    Full Information

    First Posted
    March 31, 2023
    Last Updated
    April 14, 2023
    Sponsor
    Centre Hospitalier Universitaire de Nice
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05817786
    Brief Title
    Treatment of Upper Limb Chronic Neuropathic Pain by Electrical Stimulation of the Brachial Plexus Nerve Roots
    Acronym
    SIMPLEX
    Official Title
    Treatment of Upper Limb Chronic Neuropathic Pain by Electrical Stimulation of the Brachial Plexus Nerve Roots
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    August 1, 2023 (Anticipated)
    Primary Completion Date
    May 1, 2024 (Anticipated)
    Study Completion Date
    October 1, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Centre Hospitalier Universitaire de Nice

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Moderate to severe neuropathic pain has a prevalence of 5% in the French population, involving the upper limb (UL) in 47%. Invasive neuromodulation, mainly spinal cord stimulation (SCS) is recommended as a third line treatment in refractory chronic neuropathic pain when optimized medical treatments are not sufficient to control pain. The implantation technique for BP roots PNS is based on the ultrasound-guided percutaneous inter-scalenic approach, routinely used for BP anesthetic blocks. As for SCS, BP PNS relies on chronic electrical stimulation of the nerve roots via chronically implanted devices (one lead connected to a subcutaneous generator). However efficacy of BP PNS has never been evaluated in controlled conditions. Our objectives are to assess, in controlled conditions, the effects of BP PNS in term of pain relief, quality of life improvement and safety.
    Detailed Description
    Moderate to severe neuropathic pain has a prevalence of 5% in the French population, involving the upper limb (UL) in 47% . Invasive neuromodulation, mainly spinal cord stimulation (SCS) is recommended as a third line treatment in refractory chronic neuropathic pain when optimized medical treatments are not sufficient to control pain. However, SCS implanted at the cervical level, required to control UL pain, has shown its efficacy but has specific technical issues that limit its use: lead dislocation or breakage (0-43%), lead migration (0-12,5%), unwanted paresthesias in the trunk or the lower limb(s) (17%), paresthesias changes during head movements (48%). To avoid these limitations, peripheral nerve stimulation (PNS) targeting the UL nerve trunks or nerve roots of the brachial plexus (BP) has been proposed in short pioneering series reporting encouraging results . The implantation technique for BP roots PNS is based on the ultrasound-guided percutaneous inter-scalenic approach, routinely used for BP anesthetic blocks. As for SCS, BP PNS relies on chronic electrical stimulation of the nerve roots via chronically implanted devices (one lead connected to a subcutaneous generator). In a recent prospective series of 26 patients suffering from UL refractory pain, we reported that 20 patients still using the stimulation at last follow-up (28 months) experienced a mean pain relief of 67%. Seventeen patients were improved ≥50%, including 12 improved ≥70%. Complications were rare: stimulation intolerance due to shock-like sensations, superficial infection, lead fractures and lead migration . However efficacy of BP PNS has never been evaluated in controlled conditions. Our objectives are to assess, in controlled conditions, the effects of BP PNS in term of pain relief, quality of life improvement and safety.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Neuralgia

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    randomisation at month 1
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    48 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    BP PNS (experimental group)
    Arm Type
    Experimental
    Arm Description
    Patients with refractory upper limb neuropathic pain treated by chronic electrical stimulation of the brachial plexus nerve roots
    Arm Title
    sham stimulation (control group).
    Arm Type
    Active Comparator
    Arm Description
    Patients with refractory upper limb neuropathic pain treated by sham stimulation
    Intervention Type
    Device
    Intervention Name(s)
    electrical stimulation of the brachial plexus nerve roots
    Intervention Description
    treated by chronic electrical stimulation of the brachial plexus nerve roots
    Intervention Type
    Other
    Intervention Name(s)
    sham stimulation
    Intervention Description
    treated by sham stimulation
    Primary Outcome Measure Information:
    Title
    efficacity
    Description
    evaluation by the patient with quizz EQ5D (worse: 0-better: 20)
    Time Frame
    after 3 months of treatment
    Title
    efficacity
    Description
    evaluation by the patient with quizz VAS (worse: 0- better: 100)
    Time Frame
    after 3 months of treatment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Months
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Eligibility will be determined by trained clinicians with expertise in chronic pain and neuropathic pain. Patients between 18 and 80 years old suffering from moderate to severe (VAS score >5/10) chronic (duration> 12 months) neuropathic (DN4 score ≥ 4/10) unilateral pain - located in the upper limb. from peripheral origin, including complex regional pain syndrome type I and II, post-traumatic or post surgical pain. refractory to first and second line treatments for neuropathic pain according recent French recommendations and guidelines[6], including serotonin- noradrenaline reuptake inhibitor (SNRI) antidepressants (duloxetine and venlafaxine), gabapentin, pregabalin, tricyclic antidepressants, topical lidocaine, high-concentration capsaicin patches, psychotherapy and combinations of them. Patient have signed informed consent - Patient benefiting from French social insurance system Exclusion Criteria: Brachial plexus avulsion Post-zoster neuropathic pain Phantom limb pain Patient unable to fill a self-administered questionnaire Patients with a chronic disease requiring repeated MRI monitoring Patients with contra-indication to general anesthesia, surgery or percutaneous BP approach. Patients with other pacemakers (cardiac pacemaker or defibrillator) or patients with a high risk to use a defibrillator due to a known cardiac disorder. Patients with instable neuropsychological or psychiatric disorders Vulnerable patients: pregnant or breast feeding, minor, adult under guardianship or deprived freedom
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    MARION F CAUSERET
    Phone
    0492034702
    Email
    causeret.m@chu-nice.fr
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Denys FONTAINE
    Organizational Affiliation
    Centre Hospitalier Universitaire de Nice
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Treatment of Upper Limb Chronic Neuropathic Pain by Electrical Stimulation of the Brachial Plexus Nerve Roots

    We'll reach out to this number within 24 hrs